Positive antigen peptide library for mouse ELISpot experiment as well as preparation method and application of positive antigen peptide library

The mouse ELISpot positive antigen peptide library prepared by solid-phase polypeptide synthesis method solves the problem of lack of positive antigen peptide library for mouse T cell ELISpot experiments in the prior art, and realizes CD8 in a variety of mouse strains and disease models +T cell response verification promotes the development of tumor immunotherapy.

CN118910740APending Publication Date: 2024-11-08BAIZHEN BIOTECHNOLOGY (WUHAN) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410970034.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-19
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The lack of a library of mature positive antigen peptides suitable for mouse T cell ELISpot experiments, limiting the progress of preclinical research and vaccine development.

Method used

A positive antigen peptide library for mouse ELISpot experiment was provided. 19 positive antigen peptides that can bind to MHC-I molecules were synthesized by solid-phase polypeptide synthesis method, and a peptide library that can be used to stimulate CD8+ T cells was prepared. Used to detect tumor cell immune levels.

Benefits of technology

A library of positive antigen peptides for validating the response of mouse CD8+ T cells is provided, suitable for a variety of mouse strains and disease models, helping the development of tumor immunotherapy and ensuring the effectiveness and reliability of ELISpot experiments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910740A_ABST
    Figure CN118910740A_ABST
Patent Text Reader

Abstract

The invention provides a positive antigen peptide library for a mouse ELISpot experiment as well as a preparation method and application of the positive antigen peptide library. The positive antigen peptide library consists of positive antigen peptides of which the amino acid sequences are as shown in SEQ ID NO.1-SEQ ID NO.19. The 19 positive antigen peptides provided by the invention can be combined with mouse MHCI, can cause antigen-T cell specific reaction in mice of various different strains and disease models thereof, provides positive control for immunogenicity verification of MHCI type new antigens, and assists development of tumor immunotherapy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of biochemistry, and in particular to a positive antigen peptide library for mouse ELISpot experiment and a preparation method and application thereof. Background Art

[0002] The peptides (HLAp) on the human leukocyte antigen (HLA) class I molecules on the cell surface reflect the state of the intracellular environment and changes caused by pathogenic infections or diseases. HLAp is continuously monitored by CD8+ T cells, and the identification of new T cell epitopes is a key step in the development of new therapies and vaccines for viral infections, cancer, metabolism and autoimmune diseases. For newly discovered T cell epitopes, whether they are immunogenic needs to be verified using a variety of different methods, such as ELISpot, flow cytometry, pMHC tetramers, etc., before subsequent application and treatment can be carried out. Among them, the ELISpot method is the gold standard for vaccine effectiveness. At present, there are mature commercial positive peptide mixtures such as CEF peptide library and CMV peptide library for the ELISpot method for verifying the immunogenicity of human T cell epitopes. However, as a commonly used animal model in preclinical research, the T cell ELISpot experiment of mice currently lacks a mature peptide-level positive stimulator mixture. Summary of the invention

[0003] In view of this, the present invention proposes a positive antigen peptide library suitable for T cell ELISpot experiment in an animal model - mouse, and a preparation method and application thereof, to provide support for subsequent new antigen or vaccine research.

[0004] The technical solution of the present invention is implemented as follows: In the first aspect, the present invention provides a positive antigen peptide library for mouse ELISpot experiment, wherein the positive antigen peptide library consists of positive antigen peptides with amino acid sequences as shown in SEQ ID NO.1 to SEQ ID NO.19.

[0005] On the basis of the above technical solutions, preferably, the positive antigen peptide library can bind to MHC-I class molecules and can be recognized by CD8T cells.

[0006] In a second aspect, the present invention provides a method for preparing a positive antigen peptide library for a mouse ELISpot experiment: the peptide segments of the positive antigen peptides are synthesized by a solid phase peptide synthesis method, and then the prepared positive antigen peptides are mixed in equal amounts and subsequently frozen for storage.

[0007] In a third aspect, the present invention provides the use of a positive antigen peptide library in the preparation of a product for detecting the immune level of tumor cells.

[0008] Based on the above technical solutions, preferred tumor models include but are not limited to colorectal cancer, lung cancer, pancreatic cancer, gastric cancer, kidney cancer, liver cancer and melanoma.

[0009] In a fourth aspect, the present invention provides a method for detecting the immune level of tumor cells for non-disease diagnosis purposes, using the positive antigen peptide library shown in SEQ ID NO.1 to SEQ ID NO.19 to induce a CD8+T cell response in a tumor disease model, and then using ELISpot to detect whether spots appear after stimulation, i.e., the release of IFN-γ.

[0010] The positive antigen peptide library of a mouse ELISpot experiment and its preparation method and application of the present invention have the following beneficial effects compared with the prior art:

[0011] (1) The present invention provides a positive antigen peptide library for verifying mouse CD8+T cell response using the ELISpot method, which contains 19 positive antigen peptides that can bind to mouse MHCI and induce corresponding CD8+T cells to secrete cytokines.

[0012] (2) The present invention also provides a method for preparing a positive peptide stimulator, which can induce antigen-T cell specific response in various strains of mice and their disease models, providing a positive control for the immunogenicity verification of MHCI type I new antigens, and promoting the development of tumor immunotherapy. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0014] Figure 1 This is the result of ELISpot experiment using mouse positive peptide library on monocytes extracted from spleen of C57 / B6 wild-type mice;

[0015] Figure 2 This is the result of the ELISpot experiment using the mouse positive peptide library on monocytes extracted from the spleen of C57 / B6 tumor model mice;

[0016] Figure 3 This is the result of ELISpot experiment using mouse positive peptide library on monocytes extracted from spleen of Babl / c tumor model mice. DETAILED DESCRIPTION

[0017] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0018] The present invention provides a mouse T cell epitope positive antigen peptide library, which includes 19 positive antigen peptides with a length of 8 to 12 amino acids. The specific antigen peptide amino acid sequence is as follows:

[0019] Table 1 Amino acid sequences of positive antigen peptide library

[0020]

[0021]

[0022] The peptide library preparation method is as follows:

[0023] S1, firstly, each peptide segment is synthesized using the solid phase peptide synthesis (SPPS) method. The principle is to fix the first amino acid on a solid support, and then gradually add other amino acids, and before each addition, the protecting group of the amino acid in the previous step needs to be removed. The specific process is as follows:

[0024] S11, choose the appropriate synthesis strategy

[0025] Determine the direction of synthesis: Based on the length and sequence characteristics of the polypeptide, choose to synthesize from the N-terminus to the C-terminus (N→C).

[0026] S12, introduction of protecting groups

[0027] Protecting the reactive groups of amino acids: To avoid nonspecific reactions, it is necessary to introduce protecting groups to protect the amino and carboxyl groups of amino acids during the synthesis process. The amino group is protected by Fmoc (9-fluoromethoxycarbonyl) and the carboxyl group is protected by Boc (tert-butyloxycarbonyl).

[0028] S13, activated amino acid

[0029] Increase reactivity: Activate the carboxyl group of an amino acid to increase its reactivity with the amino group of another amino acid. The activation reagents are DCC (dicyclohexylcarbodiimide) and HATU (hexafluorophosphoric acid).

[0030] S14, peptide bond formation

[0031] Connecting amino acids: Connect the activated amino acid to the amino group of another amino acid fixed on the carrier to form a peptide bond through a condensation reaction.

[0032] Repeated chain extension: Through repeated protection, activation and connection steps, the polypeptide chain is gradually extended until the polypeptide sequence is completely synthesized.

[0033] S15, Removal of Protecting Groups

[0034] Deprotection: After completing the synthesis of the polypeptide chain, the protecting groups are removed to restore the original structure of the amino acids.

[0035] Deprotection reagent: Select a suitable deprotection reagent according to the type of protecting group, specifically use a weak base (such as 20% piperidine in DMF) to remove the Fmoc protecting group and use TFA (trifluoroacetic acid) to remove the Boc protecting group, thereby restoring the original structure of the amino acid.

[0036] S16, elution and purification

[0037] Elution from the solid support: using an elution machine to elute the synthesized polypeptide from the solid support.

[0038] Purification of peptides: Peptides are purified by methods such as high performance liquid chromatography (HPLC) to remove by-products and unreacted substances during the synthesis process.

[0039] S17, Identification and Characterization

[0040] Structural identification: Mass spectrometry (MS) is used to determine the molecular weight of the peptide to ensure that the synthesized peptide meets expectations. Amino acid analysis is used to determine the amino acid composition of the peptide to further confirm its structure.

[0041] Activity verification: Conduct corresponding activity verification experiments based on the biological functions of the peptide.

[0042] S2, then take an equal amount of 50ug of each peptide segment and mix them, and use a low-temperature vacuum concentrator to freeze-dry the peptide library mixture. The freeze-drying parameters are set as follows: temperature -80°C, 16h, and -20°C storage.

[0043] When using, add 250 μL DMSO to fully dissolve, prepare a 100-fold (100X) storage solution, and store at -20°C. The final concentration used is 1X, i.e. 2 μg / mL / peptide.

[0044] Experiment 1: ELISpot experiment of mouse positive peptide library in monocytes extracted from spleen of C57 / B6 wild-type mice

[0045] The spleen of healthy C57 / B6 mice was lysed by red blood cells to extract the mononuclear cells, and then the ELISpot technology was used to detect the secretion of IFN-γ by T cells stimulated by the positive peptide library. Figure 1 The specific method is:

[0046] S1, mouse spleen mononuclear cell extraction

[0047] Select healthy, 6-8 week old C57 / B6 mice and euthanize them by carbon dioxide inhalation or cervical dislocation. Dissect the mice and remove the spleen. Then place the spleen in a culture dish and gently grind it with a cell screen (70 μm) to form a single cell suspension. Centrifuge the cell suspension, discard the supernatant, add red blood cell lysis buffer (such as ACK lysis buffer), incubate at room temperature for 5 minutes, and mix gently. Stop the lysis reaction, add sterile PBS, and centrifuge to remove the supernatant. Repeat the wash twice to ensure complete removal of the lysis buffer. Count the number of live cells using AO / PI staining and adjust the cell density to 4×10 6 cells / mL.

[0048] S2, ELISpot assay

[0049] Preparation of ELISpot plate: Use ELISpot plate with pre-coated IFN-γ capture antibody, and add appropriate amount of detection buffer (PBS containing appropriate amount of FBS) to wash and balance to block excess sites.

[0050] Add monocytes and antigen: Negative control: Add 2 × 10 5 Monocytes and appropriate amount of DMSO. Positive peptide library: add 2×10 5 Monocytes and positive antigen peptide pools. Three biological replicates were performed for each condition. Incubate at 37°C, 5% CO2 for 16-24 hours.

[0051] Detection and color development: After incubation, wash the ELISpot plate several times with wash buffer to remove unbound cells and antigens. Add biotinylated detection antibody and incubate for 1 to 2 hours. Add Streptavidin-HRP (horseradish peroxidase) followed by substrate such as NBT / BCIP or TMB. When obvious spots appear, terminate the reaction with deionized water.

[0052] Result analysis: Dry the ELISpot plate in the dark. Use an ELISpot plate reader to count the number of spots in each well, each spot representing a T cell secreting IFN-γ. Figure 1 The results showed that the positive peptide library could stimulate T cells to secrete IFN-gama.

[0053] Experiment 2: ELISpot experiment of mouse positive peptide library on monocytes extracted from spleen of C57 / B6 tumor model mice

[0054] The mouse cancer cell line was ectopically inoculated into the subcutaneous part of C57 / B6 mice to form tumors. After the tumor was successfully borne, the spleen of the tumor-bearing mouse was dissected out, and then the mononuclear immune cells in it were extracted by the red blood cell lysis method. Then, the ELISpot technology was used to detect the secretion of IFN-γ secreted by T cells stimulated by the positive peptide library. This experiment tested the secretion of IFN-γ by T cells of tumor-bearing mice corresponding to 6 different cancer cell lines stimulated by the positive peptide library, namely colorectal cancer (MC-38), lung cancer (LLC), pancreatic cancer (panc02), gastric cancer (MFC), liver cancer (Hep1-6) and melanoma (B16F10). The results are shown in Figure 2 The specific method is:

[0055] S1, Mononuclear immune cell extraction:

[0056] Healthy, 6-8 week old C57 / B6 mice were selected and inoculated with tumor cell lines. Six different cancer cell lines were prepared: MC-38 (colorectal cancer), LLC (lung cancer), panc02 (pancreatic cancer), MFC (gastric cancer), Hep1-6 (liver cancer) and B16F10 (melanoma). Cancer cells were inoculated at 1×10 7 Cells / 100 μL PBS were inoculated subcutaneously into C57 / B6 mice. The tumor growth of mice was observed regularly and the tumor volume was recorded. When the tumor reached 500-1000 mm 3 When the tumor-bearing mice were euthanized, the spleens were dissected out.

[0057] Place the spleen in a culture dish and gently grind it with a cell sieve (70 μm) to form a single-cell suspension. Centrifuge the cell suspension, discard the supernatant, add red blood cell lysis buffer (such as ACK lysis buffer), and incubate at room temperature for 5 minutes, mixing gently during the process. Stop the lysis reaction, add sterile PBS, and centrifuge to remove the supernatant. Repeat the wash twice to ensure that the lysis buffer is completely removed. Count the number of viable cells using the AO / PI staining method and adjust the cell density to 4×10 6 cells / mL.

[0058] S2, ELISpot assay

[0059] Preparation of ELISpot plate: Use ELISpot plate with pre-coated IFN-γ capture antibody, and add appropriate amount of detection buffer (PBS containing appropriate amount of FBS) to wash and balance to block excess sites.

[0060] Add monocytes and antigen: Negative control: add 2×10 5 Monocytes and appropriate amount of DMSO. Positive peptide library: add 2×10 5Monocytes and positive antigen peptide library. Test conditions: 3 biological replicates were set for each condition. Incubate at 37°C, 5% CO2 for 16-24 hours.

[0061] Detection and color development: Wash the ELISpot plate several times with wash buffer to remove unbound cells and antigens. Add biotinylated detection antibody and incubate for 1 to 2 hours. Add Streptavidin-HRP (horseradish peroxidase) followed by substrate (TMB). When obvious spots appear, terminate the reaction with deionized water.

[0062] Result analysis: The ELISpot plate was dried naturally in the dark. The number of spots in each well was counted using an ELISpot plate reader, and each spot represented a T cell secreting IFN-γ. Figure 2 The results showed that the positive peptide library could induce specific T cell responses in several common cancers.

[0063] Experiment 3: ELISpot experiment of mouse positive peptide library on monocytes extracted from spleen of Babl / c tumor model mice

[0064] In order to verify whether the positive peptide library is applicable to ELISpot experiments of tumor models constructed by other strains of mice, this experiment inoculated the renal cancer cell line recan into the subcutaneous tissue of another common mouse strain Babl / c to form tumors, and then used the ELISpot technology to verify whether the positive peptide library is applicable, the method is the same as experiment 2. The results are shown in Figure 3 . Figure 3 The results showed that the positive peptide library was also applicable to Babl / c mice.

[0065] The positive antigen peptide library provided by the present invention is suitable for various strains of mice and various disease models, including but not limited to the colorectal cancer (MC-38), lung cancer (LLC), pancreatic cancer (panc02), gastric cancer (MFC), liver cancer (Hep1-6) and melanoma (B16F10) mouse disease models mentioned in the examples, providing quality control for mouse ELISpot verification of the immunogenicity of new antigen peptides, and can be used as a quality control standard to judge the success of the ELISpot experiment.

[0066] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A positive antigen peptide library for mouse ELISpot experiment, characterized in that: The positive antigen peptide library consists of positive antigen peptides with amino acid sequences as shown in SEQ ID NO.1 to SEQ ID NO.

19.

2. The positive antigen peptide library for mouse ELISpot experiment according to claim 1, characterized in that: The positive antigen peptide library can bind to MHC-I class molecules and can be recognized by CD8T cells.

3. The method for preparing a positive antigen peptide library for mouse ELISpot experiment according to claim 1, characterized in that: The peptide segments of the positive antigen peptide are synthesized by a solid phase peptide synthesis method, and then the prepared positive antigen peptides are mixed and subsequently frozen for storage.

4. Use of the positive antigen peptide library as claimed in claim 1 in the preparation of a product for detecting the immune level of tumor cells.

5. Use of the positive antigen peptide library as claimed in claim 4 in the preparation of a product for detecting the immune level of tumor cells, characterized in that: The tumor is one of colorectal cancer, lung cancer, pancreatic cancer, stomach cancer, kidney cancer, liver cancer and melanoma.

6. A method for detecting tumor cell immune levels for non-disease diagnosis purposes, characterized in that: The positive antigen peptide library according to any one of claims 1 to 2 is used to induce CD8+T cell response in a tumor disease model, and then ELISpot is used to detect whether spots appear after stimulation, i.e., the release of IFN-γ.